Streamlining the Antibody Discovery Workflow at ImmunoPrecise Antibodies

Breakthroughs in molecular engineering and antibody humanization, have resulted in monoclonal antibodies (mAbs) becoming one of the fastest-growing classes of biopharmaceuticals for multiple clinical indications.

This highly competitive landscape necessitates the need for rapidly developing next generation antibodies against new challenging targets with improved mechanism of action, pharmacokinetics and delivery system.

Current antibody screening tools such as ELISA only report on binding, one antigen at a time, hence they are time consuming and utilize large amounts of target protein. This application note highlights how the iQue^®️ Advanced Flow Cytometry Platform enabled scientists at ImmunoPrecise Antibodies to significantly reduced their lead discovery time while conserving valuable samples and cutting down reagent cost.